Castle Biosciences, Inc.

Castle Biosciences, Inc. is a molecular diagnostics company dedicated to improving health through innovative tests that guide patient care. Founded in 2007, the company's mission is to transform disease management by providing personalized, clinically actionable information. Headquartered in Friendswood, Texas, Castle Biosciences also operates laboratory facilities in Phoenix, Arizona, and Pittsburgh, Pennsylvania.

The company specializes in proprietary molecular diagnostic tests, primarily focusing on dermatologic cancers, gastroenterology, and mental health pharmacogenomics. Key products include DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, TissueCypher Barrett's Esophagus, MyPath Melanoma, and AdvanceAD-Tx, which provide prognostic and diagnostic insights to aid in treatment decisions.

Led by Founder, President, and CEO Derek Maetzold, Castle Biosciences has recently reported strong financial performance, with Q1 2026 revenue of $83.7 million and an upward revision of full-year 2026 revenue guidance to $345–355 million. Recent achievements include the DecisionDx-Melanoma's i31-SLNB test outperforming traditional risk assessment tools, the TissueCypher Barrett's Esophagus Test surpassing 100,000 orders, and the AdvanceAD-Tx test receiving a 2026 MedTech Breakthrough Award for Genomics Innovation. The company's DecisionDx-Melanoma test also received FDA Breakthrough Device designation in July 2025.